These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 15890640)

  • 1. Targeting apoptosis pathways in cancer therapy.
    Ghobrial IM; Witzig TE; Adjei AA
    CA Cancer J Clin; 2005; 55(3):178-94. PubMed ID: 15890640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. License to kill tumors: how much hope is justified for trail?
    Frank S; Ebert AD
    Curr Pharm Des; 2001 Nov; 7(16):1689-701. PubMed ID: 11562306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1.
    Liu XW; Taube ME; Jung KK; Dong Z; Lee YJ; Roshy S; Sloane BF; Fridman R; Kim HR
    Cancer Res; 2005 Feb; 65(3):898-906. PubMed ID: 15705888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
    Dai Y; Dent P; Grant S
    Mol Pharmacol; 2003 Dec; 64(6):1402-9. PubMed ID: 14645670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK
    J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling.
    Zangemeister-Wittke U
    Ann N Y Acad Sci; 2003 Dec; 1002():90-4. PubMed ID: 14751826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook.
    Belka C; Jendrossek V; Pruschy M; Vink S; Verheij M; Budach W
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):542-54. PubMed ID: 14751526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential.
    Fiorucci G; Vannucchi S; Chiantore MV; Percario ZA; Affabris E; Romeo G
    Curr Pharm Des; 2005; 11(7):933-44. PubMed ID: 15777244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
    Kandasamy K; Srivastava RK
    Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of TRAIL signaling for cancer therapy.
    Fulda S; Debatin KM
    Vitam Horm; 2004; 67():275-90. PubMed ID: 15110182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL-induced signalling and apoptosis.
    MacFarlane M
    Toxicol Lett; 2003 Apr; 139(2-3):89-97. PubMed ID: 12628743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
    Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
    Totzke G; Schulze-Osthoff K; Jänicke RU
    Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
    Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
    Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy.
    Chinnaiyan AM; Prasad U; Shankar S; Hamstra DA; Shanaiah M; Chenevert TL; Ross BD; Rehemtulla A
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1754-9. PubMed ID: 10677530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
    Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
    Expert Opin Investig Drugs; 2001 Aug; 10(8):1521-30. PubMed ID: 11772267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.